<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) are collections of <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> characterized by refractory cytopenias as a result of ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Development of effective treatments has been impeded by limited insights into any unifying pathogenic pathways </plain></SENT>
<SENT sid="2" pm="."><plain>We provide evidence that the p38 MAP kinase is constitutively activated or phosphorylated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrows </plain></SENT>
<SENT sid="3" pm="."><plain>Such activation is uniformly observed in varied morphologic subtypes of low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and correlates with enhanced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> hematopoietic progenitors </plain></SENT>
<SENT sid="4" pm="."><plain>Most importantly, pharmacologic inhibition of p38alpha by a novel small molecule inhibitor, SCIO-469, decreases <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation </plain></SENT>
<SENT sid="5" pm="."><plain>Down-regulation of the dominant p38alpha isoform by siRNA also leads to enhancement of hematopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow progenitors in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>These data implicate p38 MAPK in the pathobiology of ineffective hematopoiesis in lowrisk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and provide a strong rationale for clinical investigation of SCIO-469 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>